Center-Authored Papers

Filters: Author is Kantoff, Philip W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R et al..  2017.  Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu J-N, Bauer S, Van Blarigan EL, Chen X et al..  2015.  Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.. Human genetics. 134(4):439-50. Abstract
D
Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin M-E, Penning TM.  2015.  The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.. Chemico-biological interactions. 234:332-8. Abstract
E
Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee G-S, Oh WK, Sartor O, Ostrander EA, Kurth T et al..  2009.  Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(9):3223-30. Abstract
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL et al..  2009.  Evaluation of the 8q24 prostate cancer risk locus and MYC expression.. Cancer research. 69(13):5568-74. Abstract
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nature genetics. 44(6):685-9. Abstract
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nature genetics. 44(6):685-9. Abstract
I
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
Pritchard CC, Mateo J, Walsh MF, DeSarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. The New England journal of medicine. 375(5):443-453. Abstract
N
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin D, Sanda M et al..  2016.  Neoadjuvant Enzalutamide Prior to Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
O
Crawford DE, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.  2015.  Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55. Abstract
P
Taplin M-E, McKay RR, Werner L, Mostaghel EA, Lis RT, Voznesensky O, Zhang Z, Marck B, Matsumoto AM, Domachevsky L et al..  2016.  A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Hsieh C-L, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M et al..  2015.  PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy.. Cancer research. 75(10):1944-8. Abstract
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2013.  Prostate cancer, version 1.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(12):1471-9. Abstract
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2014.  Prostate cancer, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):686-718. Abstract
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby EJ, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS et al..  2012.  Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(9):1081-1087. Abstract
R
Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J et al..  2015.  Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(12):1356-63. Abstract
Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.  2012.  The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.. European urology. 61(4):639-647. Abstract
S
Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee G-SM, Sun T, Peisch S, Tinianow AM, Rae JM et al..  2016.  Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 25(7):1050-1058. Abstract
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.
T
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract